Parties Dispute Science in Celexa/Lexapro MDL Preliminary Statements

ST. LOUIS, Mo. - The parties in the newly created Celexa/Lexapro MDL have submitted preliminary statements, disagreeing on the question of whether antidepressants cause suicidal behavior in patients. In re: Celexa and Lexapro Products Liability Litigation. MDL No. 1736. Case No. 4:06-md-1746 (E.D. Mo.).

On June 30, Forest Laboratories and Forest Pharmaceuticals filed its preliminary statement in the U.S. District Court for the Eastern District of Missouri, saying it had requested an MDL for the selective serotonin reuptake inhibitor (SSRIs) antidepressants to answer the question of whether reliable science proves that Celexa (citalopram HBr) and Lexapro (escitalopram oxalate) cause suicidality …